This highly informative book provides a comprehensive, up-to-date and practical reference for daily clinical practice in the management of patients affected by bone metastases. Written by renowned orthopedic surgeons and leading doctors in the respective fields of expertise, it offers a transversal review of the current medical and surgical treatments to allow a real interdisciplinary approach to the oncologic patient according to the highest current standards. The book illustrates all the fundamental medical treatments for metastatic bone diseases and provides an overview of pathology issues related to this condition. An entire section is devoted to main different methods of patients approach. It also provides guidance on all current surgical procedures and minimally invasive treatment techniques. Using a common language and recognizing the different osteoncologic competences, this work allows surgeons, oncologists, radiologists, pathologists and physiatricians to update their expertise and broaden their understanding of how a real team approach can improve the management of these oncology patients.

The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background. Armed with Clinical Trials in Oncology, Third Edition, clinicians and statisticians can avoid the many hazards that can jeopardize the success of a trial.

Edited by Clark (surgery, University of California, San Francisco, and Mount Zion Medical Center) and Noguchi (Noguchi Thyroid Clinic and Hospital Foundation), this volume explains the rationale behind currently popular treatments and clarifies the controversies surrounding the diagnosis and immediate management of patients with the disease. Presenting contributions from an international group of authorities, it contains critical outcome data, information on new diagnostic modalities, management strategies, illustrated surgical techniques, and the latest advances in molecular biology.

Written by a multidisciplinary team of experts involved in the development of standards and guidelines for its management in the USA, UK, Europe and Asia, the book contains succinct and knowledgeable summaries of the management of thyroid cancer. Every chapter describes a different aspect of care, and provides clear and detailed information about caring for patients with this group of tumors. This is an invaluable reference to health care professionals, from primary to tertiary care, involved in the management of thyroid cancer such as clinical nurse specialists, clinical psychologists, family medicine practitioners, specialists in palliative care (especially for anaplastic thyroid cancers), geneticists and surgeons, endocrinologists, oncologists, pathologists, and radiologists.

This open access book presents the history, pharmacokinetics and pharmacodynamics of levothyroxine, discussing its role in the thyroid pathophysiology of patients of various ages and during pregnancy. It also describes the influence of levothyroxine on heart, bone and in cancer. When it was first synthesized in 1949, levothyroxine represented a significant advance in the treatment of hypothyroidism, providing a safe and effective treatment option for millions of hypothyroid patients around the globe. This synthetic form of thyroxine is now one of the most prescribed drugs in the world. Levothyroxine was first introduced by Merck KGaA,Darmstadt, Germany, in 1972, and since then the company has remained actively engaged in research on this mainstay of hypothyroidism treatment. This book is intended for healthcare professionals.

Eighth volume to be published in the Essentials in Cytopathology book series. More than 115 full-color images, 12 tables and a series of algorithms. Designed to be concise and easy to use. Fits in lab coat pocket. Site specific. Illustration oriented accompanied by text in outline format. A must-have for every pathologist, cytopathologist, cytotechnologist, fellow and trainee.